Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
eFFECTOR Therapeutics, Inc. logo

OTC · EFTR

eFFECTOR Therapeutics, Inc.

Healthcare · Biotechnology

$0.00

Up+$0.00 (+0.00%)

Updated Oct 7, 2026, 1:30 AM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
941
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.00 – $0.01
Volume
1.7K
Avg. volume
3.43K

Price performance · EFTR

EFTR price history

1M range · 5 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

EFTR closed at $0.00 after 5 trading sessions, up 0.00% for the selected period.

Last close
$0.00
Period change
+0.00%
Period low
$0.00
Period high
$0.00
Daily close
View OHLC price history
EFTR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$0.0008$0.0008$0.0002$0.00021.7K
Oct 5, 2026$0.0008$0.0008$0.0008$0.0008378
Oct 1, 2026$0.0002$0.0008$0.0002$0.00025.9K
Sep 25, 2026$0.0002$0.0002$0.0002$0.0002817
Sep 16, 2026$0.0002$0.0002$0.0002$0.0002100

Latest EFTR news

The latest Smart Investors Daily articles mentioning EFTR.

Stock researchCompany · Overview

EFTR research

Overview

Company profile and research snapshot.

Company profile

EFFECTOR THERAPUTCS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
EFTR recent ratings
DateFirmRatingTarget
Mar 28, 2024HC Wainwright & Co.Buy—
Feb 6, 2024HC Wainwright & Co.Buy—
Nov 14, 2023HC Wainwright & Co.Buy—
Aug 24, 2023HC Wainwright & Co.Buy—
May 26, 2023StifelBuy—
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Nov 22, 2025

eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast

Profitability This table compares eFFECTOR Therapeutics and NexImmune's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A N/A NexImmune N/A -534.32% -213.72% Institutional and Insider Ownership 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of NexImmune shares are owned

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By